company background image
UTRS

Minerva Surgical NasdaqGM:UTRS Stock Report

Last Price

US$2.69

Market Cap

US$77.6m

7D

-0.4%

1Y

n/a

Updated

09 Aug, 2022

Data

Company Financials +
UTRS fundamental analysis
Snowflake Score
Valuation5/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

UTRS Stock Overview

Minerva Surgical, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States.

Minerva Surgical Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Minerva Surgical
Historical stock prices
Current Share PriceUS$2.69
52 Week HighUS$10.37
52 Week LowUS$1.61
Beta0
1 Month Change6.32%
3 Month Change35.18%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-70.11%

Recent News & Updates

Aug 10

Minerva downgraded at JPMorgan citing lowered guidance

After a mixed financial performance in Q2 2022, Minerva Surgical (NASDAQ:UTRS), a company focused on uterine healthcare needs of women, chose to lower its full-year guidance, a move that has prompted JPMorgan to downgrade the stock to Underweight. While results were not far short of expectations, “we are disappointed to see guidance move meaningfully lower,” the analysts led by Robbie Marcus wrote. Minerva (UTRS) offers endometrial ablation devices, Minerva ES Endometrial Ablation System, and Genesys HTA Endometrial Ablation System. The team views the decision to trim guidance as indicating a broader structural slowdown in the endometrial ablation market. That trend, a seasonal slowdown in the current quarter, and a falling cash balance led the firm to downgrade the stock. The analysts remove the price target citing the need to see better execution and YoY growth in the second half, particularly in 2023.     Minerva (UTRS) made its public debut in October for $75M in gross proceeds.

Shareholder Returns

UTRSUS Medical EquipmentUS Market
7D-0.4%-0.6%0.3%
1Yn/a-21.4%-13.5%

Return vs Industry: Insufficient data to determine how UTRS performed against the US Medical Equipment industry.

Return vs Market: Insufficient data to determine how UTRS performed against the US Market.

Price Volatility

Is UTRS's price volatile compared to industry and market?
UTRS volatility
UTRS Average Weekly Movement11.5%
Medical Equipment Industry Average Movement9.6%
Market Average Movement7.9%
10% most volatile stocks in US Market17.2%
10% least volatile stocks in US Market3.2%

Stable Share Price: UTRS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: UTRS's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2008157Dave Clapperhttps://minervasurgical.com

Minerva Surgical, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company offers Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps. Its devices are utilized by obstetrician-gynecologists in various medical treatment settings, including hospitals, ambulatory surgical centers, and physician offices.

Minerva Surgical Fundamentals Summary

How do Minerva Surgical's earnings and revenue compare to its market cap?
UTRS fundamental statistics
Market CapUS$77.57m
Earnings (TTM)-US$17.44m
Revenue (TTM)US$51.20m

1.5x

P/S Ratio

-4.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
UTRS income statement (TTM)
RevenueUS$51.20m
Cost of RevenueUS$22.10m
Gross ProfitUS$29.10m
Other ExpensesUS$46.54m
Earnings-US$17.44m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Aug 09, 2022

Earnings per share (EPS)-0.60
Gross Margin56.84%
Net Profit Margin-34.06%
Debt/Equity Ratio112.7%

How did UTRS perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is UTRS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for UTRS?

Other financial metrics that can be useful for relative valuation.

UTRS key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.8x
Enterprise Value/EBITDA-3.8x
PEG Ration/a

Price to Sales Ratio vs Peers

How does UTRS's PS Ratio compare to its peers?

UTRS PS Ratio vs Peers
The above table shows the PS ratio for UTRS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average5.8x
MLSS Milestone Scientific
7.3x18.7%US$73.9m
ELMD Electromed
2x11.7%US$78.7m
LNSR LENSAR
1.9x27.1%US$69.2m
RWLK ReWalk Robotics
11.9x37.2%US$65.7m
UTRS Minerva Surgical
1.5x24.7%US$77.6m

Price-To-Sales vs Peers: UTRS is good value based on its Price-To-Sales Ratio (1.5x) compared to the peer average (5.8x).


Price to Earnings Ratio vs Industry

How does UTRS's PE Ratio compare vs other companies in the US Medical Equipment Industry?

Price-To-Sales vs Industry: UTRS is good value based on its Price-To-Sales Ratio (1.5x) compared to the US Medical Equipment industry average (4.2x)


Price to Sales Ratio vs Fair Ratio

What is UTRS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

UTRS PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.5x
Fair PS Ratio3.5x

Price-To-Sales vs Fair Ratio: UTRS is good value based on its Price-To-Sales Ratio (1.5x) compared to the estimated Fair Price-To-Sales Ratio (3.5x).


Share Price vs Fair Value

What is the Fair Price of UTRS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: UTRS ($2.69) is trading below our estimate of fair value ($4.28)

Significantly Below Fair Value: UTRS is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies

Future Growth

How is Minerva Surgical forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-8.8%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: UTRS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: UTRS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: UTRS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: UTRS's revenue (24.7% per year) is forecast to grow faster than the US market (7.9% per year).

High Growth Revenue: UTRS's revenue (24.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if UTRS's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Minerva Surgical performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


47.9%

Last years earnings growth

Earnings and Revenue History

Quality Earnings: UTRS is currently unprofitable.

Growing Profit Margin: UTRS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if UTRS's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare UTRS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: UTRS is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (2%).


Return on Equity

High ROE: UTRS has a negative Return on Equity (-50.2%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Minerva Surgical's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: UTRS's short term assets ($61.5M) exceed its short term liabilities ($26.5M).

Long Term Liabilities: UTRS's short term assets ($61.5M) exceed its long term liabilities ($39.3M).


Debt to Equity History and Analysis

Debt Level: UTRS's net debt to equity ratio (32.4%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if UTRS's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: UTRS has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if UTRS has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies

Dividend

What is Minerva Surgical current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate UTRS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate UTRS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if UTRS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if UTRS's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as UTRS has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

5.0yrs

Average management tenure


CEO

Dave Clapper (70 yo)

11.25yrs

Tenure

US$4,423,091

Compensation

Mr. David M. Clapper, also known as Dave, has served as President and Chief Executive Officer of Minerva Surgical, Inc. since May 2011 and has served as a member of the board of directors since October 200...


CEO Compensation Analysis

Compensation vs Market: Dave's total compensation ($USD4.42M) is above average for companies of similar size in the US market ($USD763.69K).

Compensation vs Earnings: Dave's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: UTRS's management team is considered experienced (5 years average tenure).


Board Members

Experienced Board: UTRS's board of directors are considered experienced (3.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: UTRS only recently listed within the past 12 months.


Top Shareholders

Company Information

Minerva Surgical, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Minerva Surgical, Inc.
  • Ticker: UTRS
  • Exchange: NasdaqGM
  • Founded: 2008
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: US$77.565m
  • Shares outstanding: 28.83m
  • Website: https://minervasurgical.com

Number of Employees


Location

  • Minerva Surgical, Inc.
  • 4255 Burton Drive
  • Santa Clara
  • California
  • 95054
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/09 00:00
End of Day Share Price2022/08/09 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.